Functionality of probiotics - Potential for product development

被引:12
作者
Dekker, James [1 ]
Collett, Michael [1 ]
Prasad, Jaya [1 ]
Gopal, Pramod [1 ]
机构
[1] Fonterra Cooperat Grp, Palmerston North, New Zealand
来源
NUTRIGENOMICS - OPPORTUNITIES IN ASIA | 2007年 / 60卷
关键词
D O I
10.1159/000107196
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
It is becoming increasingly accepted by consumers that live lactic acid bacteria do exert health benefits when eaten. In addition, it is also becoming recognised that not all probiotic bacteria are equal. It is now no longer just a question of providing sufficient numbers of viable bacteria in a product; industry must also provide proof of efficacy for each strain. In the early 1990s, Fonterra embarked on a programme to develop proprietary probiotic strains, and as a result, commercialised two strains, Bifidobacterium lactis ITNO 19 and Lactobacillus rhamnosus ITNOO 1. Over the past decade, Fonterra has developed a significant body of peerreviewed published reports around these strains, including studies showing safety in animal and human trials, protection against pathogens such as Salmonella typhimurium and Escherichia coli O157:H7, modulation of human and animal immune markers at realistic dose rates, and efficacy in human clinical trials. Based on this work, HN019 and HN00I have been applied to several functional foods both by Fonterra (under the DRIOTm and DR20Tm brands, respectively) and by third parties (e.g. under the HOWARUTm brand by Danisco). While the 'gold standard' of proof of efficacy is a phase III clinical, trial, ethical considerations as well as expense preclude the use of clinical trials as screening tools for probiotics. Therefore, biomarkers have to be employed to identify strains with probiotic utility and to define the different positive health benefits of existing probiotic strains. However, as the mechanisms by which most probiotic bacteria exert their health benefits remain unclear, the question of which biomarkers accurately reflect efficacy in vivo remains unresolved. With recent technological advances, and the shift toward probiotics targeted to specific conditions, researchers are beginning to tease out how probiotic bacteria work, and it is this knowledge that will inform biomarker development and improve the ability to offer the market safe and effective probiotic functional foods. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:196 / 208
页数:13
相关论文
共 36 条
[1]  
Ahmed M, 2007, J NUTR HEALTH AGING, V11, P26
[2]   Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019) [J].
Arunachalam, K ;
Gill, HS ;
Chandra, RK .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2000, 54 (03) :263-267
[3]   Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019):: optimization and definition of cellular immune responses [J].
Chiang, BL ;
Sheih, YH ;
Wang, LH ;
Liao, CK ;
Gill, HS .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2000, 54 (11) :849-855
[4]   Cloning and expression of an oligopeptidase, PepO, with novel specificity from Lactobacillus rhamnosus HN001 (DR20) [J].
Christensson, C ;
Bratt, H ;
Collins, LJ ;
Coolbear, T ;
Holland, R ;
Lubbers, MW ;
O'Toole, PW ;
Reid, JR .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2002, 68 (01) :254-262
[5]   Dietary intake of Lactobacillus rhamnosus HN001 enhances production of both Th1 and Th2 cytokines in antigen-primed mice [J].
Cross, ML ;
Mortensen, RR ;
Kudsk, J ;
Gill, HS .
MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2002, 191 (01) :49-53
[6]   Can immunoregulatory lactic acid bacteria be used as dietary supplements to limit allergies? [J].
Cross, ML ;
Gill, HS .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2001, 125 (02) :112-119
[7]  
Gill H S, 2001, J Nutr Health Aging, V5, P80
[8]   Enhancement of natural and acquired immunity by Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019) [J].
Gill, HS ;
Rutherfurd, KJ ;
Prasad, J ;
Gopal, PK .
BRITISH JOURNAL OF NUTRITION, 2000, 83 (02) :167-176
[9]   Protection against translocating Salmonella typhimurium infection in mice by feeding the immuno-enhancing probiotic Lactobacillus rhamnosus strain HN001 [J].
Gill, HS ;
Shu, Q ;
Lin, H ;
Rutherfurd, KJ ;
Cross, ML .
MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2001, 190 (03) :97-104
[10]  
Gill HS, 2001, AM J CLIN NUTR, V74, P833